A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

To evaluate disease control rate (DCR) of S-1 in combination with gemcitabine in patients with advanced biliary tract cancer

Secondary Objectives:

• To evaluate overall response rate (ORR)

• To evaluate progression-free survival (PFS)

• To evaluate overall survival (OS)

• To assess the safety profile

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TTY Biopharm
• Collaborators: Chang Gung Memorial Hospital; National Cheng-Kung University Hospital; National Taiwan University Hospital; Taipei Veterans General Hospital, Taiwan
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• 1.histologically confirmed biliary tract carcinoma (including intrahepatic bile duct, extrahepatic bile duct, gallbladder, and ampulla of vater);

• 2.metastatic or unresectable disease;

• 3.no history of chemotherapy or radiotherapy for biliary tract cancer;

• 4.presence of at least one measurable tumor lesion which is defined as lesions that can be accurately measured in at least 1 dimension with longest diameter (LD) ≥20 mm using conventional techniques or ≥10 mm with spiral CT and MRI; measurable lymph nodes must be ≥15 mm in the short axis;

• 5.adequate hematopoietic function which is defined as below:

1. hemoglobin level ≥ 9 g/dL;

2. absolute neutrophil count (ANC) ≥ 1,500/mm3;

3. platelet count ≥ 100,000/mm3;

• 6.adequate hepatic function which is defined as below:

1. total bilirubin ≤ 1.5 times upper limit of normal (ULN) and < 2 mg/dL, or total bilirubin < 3 mg/dL if biliary drainage was performed;

2. Alanine aminotransferase (ALT) ≤ 3 x ULN or ALT ≤ 5 x ULN in the presence of liver metastasis;

• 7.adequate renal function: creatinine clearance rate (CCr) ≥ 60 mL/min ((based upon 24-hour urine collection or calculated by Cockroft-Gault formula);

• 8.age of 20 years or above;

• 9.ECOG performance status 0-1;

• 10.life expectancy of at least 12 weeks;

• 11.ability to take oral medication;

• 12.ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

• 1.other malignancy within the past 5 years except for adequately treated basal or squamous cell skin cancer or cervical cancer in situ;

• 2.history or known presence of brain metastasis;

• 3.presence of grade 2 or above ascites or pleural effusion;

• 4.presence of grade 2 or above diarrhea;

• 5.presence of mental disease or psychotic manifestation;

• 6.active or uncontrolled infection;

• 7.significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications based on investigator's discretion;

• 8.pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study.